MNKD-201
As of the edition of 20 October 2026, MNKD-201 is a drug known only by a code name: of no established status; acts on FGFR1, FGFR2 and FGFR3 and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| FGFR1 | Fibroblast growth factor receptor 1 | P11362 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FGFR2 | Fibroblast growth factor receptor 2 | P21802 |
| FGFR4 | Fibroblast growth factor receptor 4 | P22455 |
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Mannkind | Lead sponsor of trials | 2025 to now |